About the DocumentaryShare this page

"Approach it Like a Pro" is based on the professional practices of a leading rheumatologist, and two first-hand accounts from real patients. This brief documentary-style video explores some real-life implications of psoriatic arthritis and moderately to severely active rheumatoid arthritis, and offers exclusive insights into the treatment journey.

“It’s exciting to see improvements in signs and symptoms of moderate to severe RA and psoriatic arthritis. It helps patients gain confidence in their treatment.”
—Dr. Phil Mease
Individual results may vary.

Meet the Pros

Dr. Phil Mease
Leading rheumatologist who's helped design key clinical studies that have impacted treatment guidelines and helped establish current therapies.
Phil Mickelson
Professional golfer who worked with his doctor to take a proactive approach to managing his psoriatic arthritis.
Michelle A.
Wife and mother of five. She's also an ER nurse and health educator and has been living with moderately to severely active rheumatoid arthritis for several years.
Supportive data
Moderate to Severe Rheumatoid Arthritis

In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.

Psoriatic Arthritis

In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Important Safety Considerations

Introducing ENBREL Nurse Partners

Dedicated registered nurses are now available to give your patients the personal assistance
they need.

Here's how they can help

ENBREL is the #1 prescribed biologic by rheumatologists*

See why

*6-month average of IMS monthly NPA prescription data by rheumatologists.

IMS NPA prescription data does not include products administered by infusion.

You are leaving Enbrel.com/RheumPro
Please know that Amgen does not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy  Terms of Use
This site is intended for US Audiences only.
©2015 Amgen, Inc., Thousand Oaks, CA 91320
E-mail this page to a colleague
Please correct the fields marked in red
This content is for US health care professionals only. Amgen will not use your e-mail address or your colleague's e-mail address for any other purpose. To learn more about our use of your information and your rights, please consult our Privacy Policy.

Send another e-mail
Return to enbrel.com/RheumPro

We're sorry.

This content is not available at this time.


The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

If you are a resident of a country other than the United States, please visit the Amgen website to find information about our offices around the globe.
Phil Mickelson: A PsA patient's perspective
Disease activity vs. structural progression in RA
Treating Moderately Active RA
Rapid, Sustained Efficacy of ENBREL
Improving Outcomes in Psoriatic Arthritis
Achieving Clinical Remission
Efficacy of ENBREL Monotherapy for RA
A look back at 15 years